A Conversation With

Tim Wengerd, CFA
Director, Research Analyst, Quality Capital Reinvestment Strategies, TD Epoch

Mohamad Yatim
Director, Research Analyst, Shareholder Yield Strategies, TD Epoch

Capital Allocation in the Health Care Sector

Is the health care sector homogenous in terms of capital allocation?

The health care sector is not homogenous in its approach to capital allocation; instead, it reflects the distinct business models and operational priorities of its major subsectors – Pharmaceuticals, Biotechnology, and Managed Health Care. Pharmaceutical companies, especially large-cap firms like Bristol Myers Squibb, Eli Lilly, and Pfizer, generate substantial and relatively predictable cash flows from patented medicines. This financial strength enables them to fund extensive research and development (R&D) to sustain their product pipelines while also returning significant portions of earnings to shareholders through dividends and share repurchases. Their ability to balance reinvestment in innovation with shareholder returns sets them apart within the sector.

Biotechnology companies, by contrast, are typically younger, more R&D-focused, and have fewer marketed products. Their capital allocation strategies prioritize reinvesting or conserving cash to fund ongoing research and clinical trials rather than distributing earnings to shareholders. Only a handful of mature, profitable biotech firms can offer shareholder yields comparable to big pharma; for the broader Biotech sector, investor returns are driven mainly by long-term equity appreciation tied to pipeline success rather than immediate cash distributions like dividends or buybacks. This results in a capital allocation profile that is heavily skewed toward innovation and future growth.

Managed Health Care companies – including insurers and health care service providers – operate under a different model. Their capital allocation is not centered on R&D, but instead focuses on managing operational costs, maintaining strong liquidity to cover insurance claims, and returning value to shareholders through consistent dividends and share repurchases. With more predictable revenue streams and minimal R&D requirements, these firms can provide steady, growing returns to shareholders while ensuring their dividend policies are rarely disrupted, even in the face of medical cost fluctuations, thanks to disciplined pricing and reserve management.

What is the state of capital allocation in the Pharmaceutical and Biotech subsectors?

The state of capital allocation in the Pharmaceutical and Biotech subsectors reflects a distinct investment environment marked by long timelines, high risk, and substantial variability in returns. Unlike industries where capital investments generate quick paybacks, drug development in these subsectors often spans a decade or more, requiring extensive R&D, lengthy clinical trials, and navigation of rigorous regulatory processes. As a result, typical Return on Invested Capital (ROIC) is generally lower in the early phases, with many projects failing to reach commercialization. However, the emergence of a blockbuster drug can dramatically alter a company's fortunes, generating billions in revenue and significantly boosting ROIC, thus introducing considerable volatility into the sector's capital allocation outcomes.

To manage these risks, pharmaceutical companies typically maintain diversified pipelines, allocating capital across numerous projects to increase the likelihood of success. Mature, large-cap pharma firms – such as Roche, Sanofi and Novo Nordisk – demonstrate a balanced approach by generating strong cash flows that support both significant shareholder returns and continued investment in innovation. These companies often pay out 40% to 60% of net income through dividends and share buybacks while maintaining robust R&D budgets, allocating approximately 15% to 25% of revenues to sustain their pipelines and address challenges like patent expirations. For instance, one Swiss pharma company has consistently increased its dividend for nearly four decades while keeping R&D investment near 20% of sales, showcasing the sector's ability to deliver income stability and ongoing growth.

Growth in large-cap pharma is also fueled by acquisitions, particularly of smaller innovative biotechs. These deals often target early-stage assets to complement internal discovery efforts, though companies facing pipeline gaps may pursue high-value acquisitions of late-stage biotechs, which introduces additional valuation and execution risks. The dual mandate of returning capital to shareholders and investing for future growth underpins the enduring appeal of major pharma companies for investors seeking both yield and long-term upside.

In contrast, biotech firms – especially younger or early-stage companies – typically reinvest the vast majority of their capital into R&D and clinical development, leaving little for direct shareholder returns such as dividends or buybacks. These companies often rely on venture funding or stock offerings to support their research-intensive business models. For investors, the biotech sector is primarily about optionality and the potential for asymmetric upside, with value creation hinging on the successful commercialization of scientific breakthroughs.

As some biotechs mature and diversify their revenue streams, their capital allocation strategies evolve to resemble those of established pharmaceutical companies. Notable examples like Amgen and Gilead have transitioned into cash-generative enterprises, employing a disciplined mix of dividend growth, share repurchases, and debt reduction. This shift reflects the steady-state economics of their established product portfolios and the reduced R&D risk that comes with maturity. For instance, one California based biotech has emphasized shareholder returns as a central pillar of its capital strategy, supported by robust free cash flow and greater financial flexibility following strategic acquisitions.

What is the state of capital allocation in the Managed Health Care subsector?

Managed Health Care firms, including major players like UnitedHealth Group and CVS Health, have a capital allocation strategy that is distinct from their pharmaceutical and biotechnology counterparts. These companies prioritize maintaining liquidity to cover claim liabilities, focusing less on speculative R&D and more on operational efficiency and premium income. Their first obligation, as regulated insurers, is to ensure balance sheet strength by maintaining statutory capital and reserves necessary to pay members' health care claims, even during periods of elevated utilization. Once these obligations are met, they deploy excess cash through steady dividend growth, share repurchases, and occasionally debt paydown, creating a reliable stream of shareholder yield. This capital-light model does not require funding massive physical plants or extensive in-house R&D portfolios, but it is not without risk; spikes in medical costs, such as increased outpatient utilization, can immediately pressure margins. Management typically addresses these pressures by adjusting premiums, networks, or plan designs in subsequent contract cycles rather than reducing dividends.

Growth in the Managed Health Care sector is driven heavily by acquisition and integration, expanding into areas like care delivery, specialty pharmacy, home health, and advanced analytics to diversify earnings and enhance operational scale. Scale in specific markets or business lines is crucial for earning attractive ROIC and companies achieve this through mergers and by efficiently serving both patients and payers. For long-term investors, Managed Health Care offers an appealing combination of steady dividend growth, disciplined balance sheet management, and robust cash generation, without the R&D intensity or patent risk seen in pharmaceuticals. However, the sector remains sensitive to claim trends, pricing regulations, and policy shifts, all of which influence its ability to sustain consistent and compounding shareholder returns.

Are the trends in any of the other subsectors significantly different than the ones mentioned above?

The trends in health care subsectors beyond Pharma, Biotech, and Managed Health Care reveal distinct differences shaped by each segment's capital allocation priorities and operational realities. Medical device companies, or MedTech firms, such as Medtronic and Johnson & Johnson, focus heavily on innovation and manufacturing, with stable and recurring cash flows supported by entrenched clinical usage and brand trust. Their approach to capital allocation differs from Pharma's R&D-driven model and Managed Health Care's emphasis on liquidity. MedTech companies generally maintain lower R&D intensity than pharmaceutical firms, which allows for consistent dividend growth and disciplined capital returns. For example, one American-Irish MedTech firm has raised its dividend for 48 consecutive years, demonstrating a commitment to reliability and compounding shareholder value over yield maximization. In addition to dividends, these companies often pursue share repurchases and modest debt reduction, while reserving meaningful capital for tuck-in acquisitions to drive product innovation. Much of MedTech's advancement comes from acquiring smaller companies with differentiated technologies that can be scaled globally, rather than relying solely on internal discovery.

Life Science Tools & Services companies, such as Thermo Fisher, Danaher, and Illumina, exhibit a capital allocation strategy that leans more toward growth orientation. Their substantial free cash flow is frequently reinvested into acquisitions, capacity expansion, and technology upgrades. While shareholder yield exists, the primary focus for these firms is strategic reinvestment and growth, with management prioritizing long-term expansion over near-term payouts.

Other health care segments, such as home health care and health services, prioritize operational scalability and workforce investment. These firms often experience steadier cash flows compared to the volatile pipelines typical of biotech companies, reflecting a more predictable business model. Their capital allocation strategies contrast with the R&D intensity seen in the Pharma and Biotech sectors, focusing instead on efficient delivery and scaling of services to meet evolving patient needs.

Are there factors on the horizon that might impact capital allocation?

Several factors on the horizon are poised to significantly impact capital allocation in the health care sector. Regulation remains a key driver – potential changes such as new drug pricing reforms or updated medical device standards could prompt pharmaceutical and biotech companies to reallocate funds, often moving resources away from traditional R&D efforts. Government influence, including expansions of Medicare coverage or increased subsidies, could further shift capital toward favored subsectors. Additionally, rising global life expectancy is expected to boost demand for long-term care and chronic disease management, encouraging firms to channel investments into these areas.

Technological advancements, particularly the emergence of artificial intelligence (AI), are reshaping capital allocation strategies across health care. AI is already compressing critical components of drug discovery and development, allowing companies to focus spending on fewer, higher-conviction programs rather than broad, costly compound screening. This shift is redirecting capital toward data assets, computational infrastructure, and partnerships with AI-native discovery platforms. Furthermore, AI is making clinical development and manufacturing more efficient by enhancing patient recruitment, optimizing site selection, and streamlining operations through predictive maintenance. While core manufacturing capabilities remain essential – especially for advanced therapies – the selective deployment of incremental capital promises higher expected returns.

Economic pressures such as inflation and interest rate changes may also constrain borrowing capacity, incentivizing firms to retain more cash and exercise greater financial discipline. These evolving dynamics introduce uncertainty and require health care companies to carefully balance innovation, operational stability, and shareholder returns. Importantly, the adoption of AI is set against the backdrop of ongoing drug pricing scrutiny, reimbursement pressures, and policy risks, which may limit how aggressively increased cash flow can be returned to investors.

Nevertheless, the broader outlook is attractive: secular trends like aging demographics and continuous technological progress are fueling demand and reducing the cost to serve, supporting both reinvestment and disciplined capital returns. Within this environment, firms best positioned to thrive are those with strong balance sheets and the ability to leverage AI-enabled productivity into durable free cash flow and growing shareholder distributions. Ultimately, the interplay of regulatory changes, government influence, demographic shifts, technological innovation, and economic factors will shape the future of capital allocation in the healthcare sector, compelling companies to remain adaptive and focused on sustainable value creation.

Learn more about TD Global Investment Solutions

www.tdgis.com